News & Opinion
There are three articles in the June issue of Bioethics on different aspects of ghostwriting.
The first article, by Tobenna D Anekwe, “Profits and plagiarism: the case of medical ghostwriting” argues that “medical ghostwriting often involves plagiarism and, in those cases, can be treated as an act of research misconduct” and suggests measures to counter ghostwriting.
The news story reports that the National Council on Ethics in Human Research (NCEHR), has had its funding withdrawn by Health Canada and the Canadian Institutes of Health Research. Apparently this will primarily affect education, but also scotches the possibility that the Council would devolp into a Canadian national accrediting and oversight body for research ethics boards.
The story relates to an announcement on June 10 by the International Federation of Pharmaceutical Manufacturers and Associations. An exerpt from the IFPMA press release states:
We received this report from Behrooz Astaneh, Deputy Editor of the Iranian Journal of Medical Sciences.
Behrooz can be contacted on [email protected]
The second seminar of Iranian Medical Journal editors- A Report
Well worth reading. http://www.trialsjournal.com/content/pdf/1745-6215-11-37.pdf
The overall message and the recommendations aren't new, but thus is a succinct and informative review by the German health technology asessement body that's worth citing and using in talks. It includes and goes well beyond the usual suspects (rofecoxib, gabapentin, SSRIs, rosiglitazone, oseltamivir) and gives a really nice overview of all the recent attempts to make people behave better eg through trial registration.